A study published this week in Nature sheds new light on the connection between the gut and the brain, untangling the complex interplay that allows the byproducts of microorganisms living in the gut to influence the progression of neurodegenerative diseases. Investigators from Brigham and Women's Hospital (BWH) have been using both animal models and human cells from patients to tease out the key players involved in the gut-brain connection as well as in the crosstalk between immune cells and brain cells. Their new publication defines a pathway that may help guide therapies for multiple sclerosis and other neurologic diseases.
"These findings provide a clear understanding of how the gut impacts central nervous system resident cells in the brain," said corresponding author Francisco Quintana, PhD, of the Ann Romney Center for Neurologic Diseases at BWH. "Now that we have an idea of the players involved, we can begin to go after them to develop new therapies."
The new research focuses on the influence of gut microbes on two types of cells that play a major role in the central nervous system: microglia and astrocytes. Microglia are an integral part of the body's immune system, responsible for scavenging the CNS and getting rid of plaques, damaged cells and other materials that need to be cleared. But microglia can also secrete compounds that induce neurotoxic properties on the star-shaped brain cells known as astrocytes. This damage is thought to contribute to many neurologic diseases, including multiple sclerosis.
Brigham researchers have previously explored the gut-brain connection to gain insights into multiple sclerosis. Although some studies have examined how byproducts from organisms living in the gut may promote inflammation in the brain, the current study is the first to report on how microbial products may act directly on microglia to prevent inflammation. The team reports that the byproducts that microbes produce when they break down dietary tryptophan - an amino acid found in turkey and other foods - may limit inflammation in the brain through their influence on microglia.
To conduct their study, the research team examined gut microbes and the influence of changes in diet in a mouse model of multiple sclerosis. They found that compounds resulting from the breakdown of tryptophan can cross the blood-brain barrier, activating an anti-inflammatory pathway that limits neurodegeneration. The researchers also studied human multiple sclerosis brain samples, finding evidence of the same pathway and players.
Activation of this same pathway has recently been linked to Alzheimer's disease and glioblastoma. The Ann Romney Center for Neurologic Diseases, of which Quintana is a part, brings experts together to accelerate treatment for these diseases, as well as multiple sclerosis Parkinson's disease and ALS (Lou Gehrig's disease).
"It is likely the mechanisms we've uncovered are relevant for other neurologic diseases in addition to multiple sclerosis," said Quintana. "These insights could guide us toward new therapies for MS and other diseases."
Quintana and his colleagues plan to further study the connections to neurologic diseases, and are also optimizing small molecules as well as probiotics to identify additional elements that participate in the pathway and new therapies.
###
This work was supported by grants NS087867, ES02530, AI126880 and AI093903 from the National Institutes of Health; RSG-14-198-01-LIB from the American Cancer Society; RG4111A1 and JF2161-A-5 from the National Multiple Sclerosis Society; a Collaborative Network Award from the International Progressive MS Alliance; an educational grant from Mallinkrodt Pharmaceuticals (A219074); fellowship from the German Research Foundation (DFG RO4866 1/1); the BMBF-funded competence network of multiple sclerosis (KKNMS); the Sobek-Stiftung; the DFG (SFB 992, SFB1140, SFB/TRR167, Reinhart-Koselleck-Grant); and the Ministry of Science, Research and the Arts, Baden-Wuerttemberg. The authors declare no competing financial interests.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.
Journal
Nature